Huadong Medicine and SynerK to jointly develop a novel siRNA drug SNK-2726
SynerK owns intellectual property rights of SNK-2726, which is currently in the IND filing preparation stage
SynerK owns intellectual property rights of SNK-2726, which is currently in the IND filing preparation stage
Expects to unlock further opportunities in the Moldovan market, contributing anticipated sales of $300,000 in 2025 and approximately $700,000–$800,000 in 2026
In 2020, CORXEL acquired the rights to develop and commercialize aficamten in Greater China
Parents, teachers, and caregivers play a vital role in spotting early signs of schizophrenia
Smeeta Bhatkal, Santosh Desai and Akshay Kumar join as Independent Directors; Shaina NC as Non-Executive Director
Infections with H. pylori affect over 43 percent of the world’s population with a wide range of gastrointestinal disorders
Thyrocare becomes first national diagnostic chain with 100% of its labs with NABL accreditation
JCI accreditation is recognized globally
The technical program will run in four sessions and a panel discussion on “Challenges in translation of medical technologies”
Subscribe To Our Newsletter & Stay Updated